Streetbeat News

KZIA

Kazia Therapeutics Limited

https://www.kaziatherapeutics.com

Industry

Biotechnology

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Open

1.01

Mkt cap

3.2M

Volume

32K

High

1.01

P/E Ratio

-0.15

52-wk high

15.80

Low

0.94

Div yield

N/A

52-wk low

0.76

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Theriva Biologics, Conduit Pharmaceuticals, and ENDRA Life Sciences were among the top gainers, while Windtree Therapeutics, Soligenix, and Kazia Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 12:06 pm

Kazia Therapeutics shares rose following the presentation of positive Phase I study data on paxalisib combined with radiation therapy for treating certain brain metastases at a major oncology conference.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 3:15 pm

Kazia Therapeutics presented promising Phase I data at the American Society for Radiation Oncology meeting, showing that treatment with paxalisib and radiotherapy achieved a 67% partial response in patients with brain metastases. This compares favorably to historical response rates for radiation therapy alone.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 12:48 pm

Kazia Therapeutics Limited (NASDAQ:KZIA) presented promising clinical data for EVT801, a VEGFR3 inhibitor, at the 15th Biennial Ovarian Cancer Research Symposium. The Phase 1 trial showed EVT801's safety and tolerability, with encouraging results in high grade serous ovarian cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 12:31 pm

Kazia Therapeutics shares rose following the announcement of a licensing agreement with QIMR Berghofer Medical Research Institute.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:49 am

Kazia Therapeutics has entered into an agreement with QIMR Berghofer Medical Research Institute to obtain an exclusive license for intellectual property rights related to combination therapies involving Pi3K inhibitor drugs and immunotherapy or PARP inhibitor drugs.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 11:37 am

SolarEdge Technologies, Inc. (NASDAQ:SEDG) shares fell 12.2% after announcing a workforce reduction of 400 employees. Other notable stock movements include Autonomix Medical, Inc. (NASDAQ:AMIX) climbing 148% and Trump Media & Technology Group Corp. (NASDAQ:DJT) rising 32.8% following an attempted assassination of Donald Trump.

Portfolio Pulse from Avi Kapoor

July 15, 2024 | 5:23 pm

Kazia Therapeutics Limited (NASDAQ:KZIA) will present new data from its lead program, paxalisib, at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) from June 29 to July 2, 2024. Additionally, an article in the European Journal of Cancer highlights the need for mutation-specific, CNS-penetrant inhibitors to treat pediatric patients with Diffuse Midline Glioma (DMG).

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:17 pm

Kazia Therapeutics has received a 180-day extension from Nasdaq to meet the minimum bid price requirement, with a new deadline set for November 18, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 6:46 pm

Kazia Therapeutics has been granted an additional 180 days by Nasdaq to regain compliance with the Minimum Bid Price Requirement. The company has until November 18, 2024, to ensure its stock price meets the $1.00 per share minimum for 10 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 11:14 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.